The choice of HiGHmed’s three medical use cases oncology, cardiology and infection control were based on the rationale that each of them would prototypically allow HiGHmed to address a variety of specific challenges and requirements in Medical Informatics. In addition, it reflects the complementary strength of the partner sites, thus providing an ideal basis for collaboration.
The oncology use case will address challenges in Medical Informatics when integrating omics data from genome sequencing and radiology into clinical practice. These data types have begun to reshape tumor diagnostics and treatment. But the sheer volume of genomics and radiomics data presently hampers translation into wider clinical practice, an issue that will be addressed. The implementation of a virtual oncology center will allow sharing and visualization of information about a patient’s course of treatment to identify similar cases in the future.
New, mobile diagnostic devices are expected to enhance current medical practice and research by contributing to the long-term monitoring of personal health data at an unprecedented level. Within the cardiology use case, longitudinal data from hospitals, health insurance companies, new sensors and patient-reported outcome will be integrated into our IT architecture to better identify patients at high-risk and to reduce mortality resulting from heart failure.
The infection control use case will develop an automated early warning and cluster analysis system to support the algorithmic detection of pathogen clusters in hospitals. It will include multidrug-resistant organism clusters within and across university/non-university hospitals, verification of whether clusters represent actual outbreaks, and the investigation of possible causes of outbreaks. This motivates us to address IT challenges when connecting and analyzing multiple clinical and organizational data sources for establishing spatial, temporal, biological and functional associations.
Importantly, our technology platforms will be developed in a generic way in order to fully support these three, as well as various other, medical use cases. All the partners will therefore benefit from this integrated technology platform with immediate added value for the three communities of clinicians, patients and researchers.